|
|
Volumn 13, Issue 6, 2007, Pages 745-749
|
|
The economics of haemophilia prophylaxis: Governmental and insurer perspectives. Proceedings of the second international prophylaxis study group (IPSG) symposium
a,e
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BLOOD CLOTTING FACTOR 8;
BLOOD CLOTTING FACTOR 8 CONCENTRATE;
BLOOD CLOTTING FACTOR 9;
RECOMBINANT BLOOD CLOTTING FACTOR 8;
BLEEDING;
BLOOD TRANSFUSION;
CONFERENCE PAPER;
COST EFFECTIVENESS ANALYSIS;
GERMANY;
HEALTH CARE COST;
HEALTH CARE NEED;
HEALTH CARE PLANNING;
HEALTH CARE POLICY;
HEALTH CARE QUALITY;
HEALTH PROGRAM;
HEMOPHILIA;
HUMAN;
MEDICARE;
PATIENT SAFETY;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
QUALITY OF LIFE;
RECOMMENDED DRUG DOSE;
UNITED KINGDOM;
COST-BENEFIT ANALYSIS;
GREAT BRITAIN;
HEALTH POLICY;
HEMOPHILIA A;
HUMANS;
INSURANCE, HEALTH;
NORTH AMERICA;
|
|
EID: 35548935570
PISSN: 13518216
EISSN: 13652516
Source Type: Journal
DOI: 10.1111/j.1365-2516.2007.01542.x Document Type: Conference Paper |
|
Times cited : (20)
|
|
References (3)
|
